Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.

ABSTRACT:

Objective

To investigate the efficacy and safety of belimumab in the treatment of systemic lupus erythematosus (SLE) in a real-world setting and provide a valuable reference for clinical treatment.

Methods

In this retrospective study, 101 patients with SLE who came to our hospital from March 2020 to September 2022, 56 of whom with lupus nephritis (LN), were selected. All patients received belimumab in combination with standard of care(SoC)therapy regimen for more than 52 weeks and their clinical/laboratory data, assessment of disease activity, glucocorticoids dosage and occurrence of adverse events were recorded. Lupus Low Disease Activity State (LLDAS) and DORIS remission as a primary goal in the treatment of SLE. The groups were classified according to the Systemic Lupus E

SUBMITTER: Su Z 

PROVIDER: S-EPMC11409747 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature